303 related articles for article (PubMed ID: 27298402)
1. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
Sarkozy C; Trneny M; Xerri L; Wickham N; Feugier P; Leppa S; Brice P; Soubeyran P; Gomes Da Silva M; Mounier C; Offner F; Dupuis J; Caballero D; Canioni D; Paula M; Delarue R; Zachee P; Seymour J; Salles G; Tilly H
J Clin Oncol; 2016 Aug; 34(22):2575-82. PubMed ID: 27298402
[TBL] [Abstract][Full Text] [Related]
2. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
3. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
4. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
5. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
6. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.
Montoto S; Davies AJ; Matthews J; Calaminici M; Norton AJ; Amess J; Vinnicombe S; Waters R; Rohatiner AZ; Lister TA
J Clin Oncol; 2007 Jun; 25(17):2426-33. PubMed ID: 17485708
[TBL] [Abstract][Full Text] [Related]
7. [Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia].
Nesterova ES; Kravchenko SK; Mangasarova YK; Baryakh EA; Misyurina AE; Vorobyev VI; Plastinina LV; Chernova NG; Kovrigina AM; Obukhova TN; Klyasova GA; Shevelev AA; Kostina IE; Gemdzhian EG; Gaponova TV; Vorobyev AI
Ter Arkh; 2016; 88(7):62-71. PubMed ID: 27459617
[TBL] [Abstract][Full Text] [Related]
8. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
9. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
Link BK; Maurer MJ; Nowakowski GS; Ansell SM; Macon WR; Syrbu SI; Slager SL; Thompson CA; Inwards DJ; Johnston PB; Colgan JP; Witzig TE; Habermann TM; Cerhan JR
J Clin Oncol; 2013 Sep; 31(26):3272-8. PubMed ID: 23897955
[TBL] [Abstract][Full Text] [Related]
10. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
Trotman J; Fournier M; Lamy T; Seymour JF; Sonet A; Janikova A; Shpilberg O; Gyan E; Tilly H; Estell J; Forsyth C; Decaudin D; Fabiani B; Gabarre J; Salles B; Van Den Neste E; Canioni D; Garin E; Fulham M; Vander Borght T; Salles G
J Clin Oncol; 2011 Aug; 29(23):3194-200. PubMed ID: 21747087
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study.
Casulo C; Herold M; Hiddemann W; Iyengar S; Marcus RE; Seymour JF; Launonen A; Knapp A; Nielsen TG; Mir F
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):40-48. PubMed ID: 36379880
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with transformed lymphoma.
Montoto S
Hematology Am Soc Hematol Educ Program; 2015; 2015():625-30. PubMed ID: 26637780
[TBL] [Abstract][Full Text] [Related]
14. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
15. Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma.
Alonso-Álvarez S; Manni M; Montoto S; Sarkozy C; Morschhauser F; Wondergem MJ; Guarini A; Magnano L; Alcoceba M; Chamuleau M; Galimberti S; Gomes da Silva M; Holte H; Zucca E; Lockmer S; Aurer I; Marcheselli L; Stepanishyna Y; Caballero Barrigón MD; Salles G; Federico M
Eur J Cancer; 2021 Nov; 157():132-139. PubMed ID: 34508995
[TBL] [Abstract][Full Text] [Related]
16. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.
Miao Y; Hu S; Lu X; Li S; Wang W; Medeiros LJ; Lin P
Hum Pathol; 2016 Dec; 58():72-77. PubMed ID: 27544800
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group.
Popovic S; Jovanovic D; Mihaljevic B; Andjelkovic N; Marjanovic G; Marisavljevic D; Vlaisavljevic N; Popovic L; Salma S; Agic D; Milosevic R; Smiljanic M; Sretenović S; Djurdjević P; Markovic O; Hajder J; Govedarovic N
J BUON; 2017; 22(2):487-494. PubMed ID: 28534374
[TBL] [Abstract][Full Text] [Related]
18. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
[TBL] [Abstract][Full Text] [Related]
19. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.
Pham RN; Gooley TA; Keeney GE; Press OW; Pagel JM; Greisman HA; Bensinger WI; Holmberg LA; Petersdorf SH; Maloney DG; Gopal AK
Bone Marrow Transplant; 2007 Dec; 40(11):1039-44. PubMed ID: 17922043
[TBL] [Abstract][Full Text] [Related]
20. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
